文献速递免疫规划传染病防控与疫情报告

6月龄至5岁儿童接种mRNA COVID-19疫苗第三剂的安全性监测——美国,2022年6月17日至2023年5月7日

Safety Monitoring of mRNA COVID-19 Vaccine Third Doses Among Children Aged 6 Months-5 Years - United States, June 17, 2022-May 7, 2023.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2023-06-09

CDC分析了2022年6月17日至2023年5月7日期间6月龄至5岁儿童接种第三剂mRNA COVID-19疫苗后v-safe和VAERS报告的安全性数据。v-safe中2969名儿童约37.7%无报告反应,报告的反应多为轻微且短暂;VAERS收到536份报告,98.5%为非严重,78.4%为接种错误。未发现新的安全担忧。

要点

  • 6月龄至5岁儿童接种第三剂mRNA COVID-19疫苗后,v-safe中约37.7%无报告反应,报告的反应多为轻微且短暂。
  • VAERS收到536份第三剂后报告,98.5%为非严重,78.4%为接种错误。
  • 未发现新的安全担忧,初步安全性与其他剂次相似。

核心结论

  • 6月龄至5岁儿童接种第三剂mRNA COVID-19疫苗后未发现新的安全担忧,初步安全性与其他剂次相似。

研究设计与样本

  • CDC审查了2022年6月17日至2023年5月7日期间向v-safe和VAERS报告的6月龄至5岁儿童第三剂mRNA COVID-19疫苗接种后不良事件和健康调查。
  • 期间约495576名6月龄至4岁儿童接种了第三剂辉瑞-BioNTech疫苗,63919名6月龄至5岁儿童接种了第三剂Moderna疫苗。

主要发现

  • v-safe中记录了2969名儿童接种第三剂mRNA COVID-19疫苗,约37.7%无报告反应,报告的反应多为轻微且短暂。
  • VAERS收到536份该年龄段儿童第三剂mRNA COVID-19疫苗后报告,98.5%为非严重,78.4%被归类为接种错误。

关键数值与推荐

  • 截至2023年5月7日,CDC免疫实践咨询委员会(ACIP)推荐所有6月龄至5岁儿童至少接种1剂适龄二价mRNA COVID-19疫苗。
  • 根据COVID-19疫苗接种史和免疫缺陷史,这些儿童可能还需要额外剂次。

临床怎么用

  • 卫生保健提供者可告知幼儿父母和监护人,接种辉瑞-BioNTech或Moderna疫苗后报告的大多数反应为轻微且短暂,严重不良事件罕见。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As of May 7, 2023, CDC's Advisory Committee on Immunization Practices (ACIP) recommends that all children aged 6 months-5 years receive at least 1 age-appropriate bivalent mRNA COVID-19 vaccine dose. Depending on their COVID-19 vaccination history and history of immunocompromise, these children might also need additional doses* (1-3). Initial vaccine safety findings after primary series vaccination among children aged 6 months-5 years showed that transient local and systemic reactions were common whereas serious adverse events were rare (4). To characterize the safety of a third mRNA COVID-19 vaccine dose among children aged 6 months-5 years, CDC reviewed adverse events and health surveys reported to v-safe, a voluntary smartphone-based U.S. safety surveillance system established by CDC to monitor health after COVID-19 vaccination (https://vsafe.cdc.gov/en/) and the Vaccine Adverse Event Reporting System (VAERS), a U.S. passive vaccine safety surveillance system co-managed by CDC and the Food and Drug Administration (FDA) (https://vaers.hhs.gov/) (5). During June 17, 2022-May 7, 2023, approximately 495,576 children aged 6 months-4 years received a third dose (monovalent or bivalent) of Pfizer-BioNTech vaccine and 63,919 children aged 6 months-5 years received a third dose of Moderna vaccine.† A third mRNA COVID-19 vaccination was recorded for 2,969 children in v-safe; approximately 37.7% had no reported reactions, and among those for whom reactions were reported, most reactions were mild and transient. VAERS received 536 reports after a third dose of mRNA COVID-19 vaccine for children in these age groups; 98.5% of reports were nonserious and most (78.4%) were classified as a vaccination error.§ No new safety concerns were identified. Preliminary safety findings after a third dose of COVID-19 vaccine for children aged 6 months-5 years are similar to those after other doses. Health care providers can counsel parents and guardians of young children that most reactions reported after vaccination with Pfizer-BioNTech or Moderna vaccine were mild and transient and that serious adverse events are rare.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Hause AM, Marquez P, Zhang B, et al. Safety Monitoring of mRNA COVID-19 Vaccine Third Doses Among Children Aged 6 Months-5 Years - United States, June 17, 2022-May 7, 2023. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37289661. doi:10.15585/mmwr.mm7223a2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。